In particular, the complaint
alleges that throughout the Class Period, defendants made materially false and / or misleading statements and / or failed to disclose that (1) the trials for GED - 0301 suffered from fatal design
defects, such that GED - 0301 had failed to demonstrate meaningful clinical efficacy; (2) the growth of Otezla sales had dramatically slowed during Celgene's third fiscal quarter of 2017; and (3) the clinical and nonclinical pharmacology data in Celgene's new drug application («NDA») for Ozanimod were insufficient to permit a complete review by the FDA, which resulted in the FDA issuing a refusal to file letter to Celgene
regarding the NDA.
Our team is experienced in underground storage tank regulation and litigation of actions brought pursuant to California Proposition 65, the Federal Clean Water Act and various state environmental laws and tort doctrines, including actions
alleging contamination, product
defect and failure to warn
regarding methyl tertiary butyl ether («MTBE»).